TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02483624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-DIM
Description: DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR-DIM
Description: DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01358760

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo vaginal suppository

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.25% (3.25 mg) DHEA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DHEA
Description: Vaginal suppository containing 0.5% (6.5 mg) DHEA
Study: NCT02794077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
Study: NCT00961753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized ibuprofen
Description: day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
Study: NCT00598260

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: induction of labor
Description: study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
Study: NCT00517153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: miglustat
Description: Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
Study: NCT04169490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Cream Base Emulsion Moisturizer
Description: Topical placebo white, oil/water emulsion moisturizer applied b.d. for 120 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FS2 Emulsion Moisturizer
Description: Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator Onion Skin Extract Gel (Mederma)
Description: Topical onion skin extract gel (Mederma) applied b.d. for 120 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator Silicone Gel (Kelo-Cote)
Description: Topical silicone gel (Kelo-Cote) applied b.d. for 120 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Comparator Silicone Gel (Kelo-Cote) + FS2 Emulsion Moisturizer
Description: Topical silicone gel (Kelo-Cote) + Topical FS2 white, oil/water emulsion moisturizer applied b.d. for 120 days
Study: NCT04444960

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention
Description: Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients

Intervention type: PROCEDURE
Intervention: percutaneous coronary intervention
Description: Intracoronary physiology and imaging-guided intervention strategy versus angiography-guided intervention strategy for complex high-risk coronary heart disease patients
Study: NCT01925352

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad-HGF
Description: 5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
Study: NCT01637909

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.
Description: All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Treatment group 1(Dietary intervention)
Description: The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment group 2(dietary and exercise intervention)
Description: The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
Study: NCT02019823

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational SMS-text

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Informational SMS-text

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive SMS-text

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced usual care
Study: NCT01212978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer to Increase Physical Activity
Description: The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pedometer to Increase Physical Activity
Description: The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
Study: NCT04297501

Intervention type: DRUG
Intervention: Antiretroviral Therapy
Description: All participants receive antiretroviral therapy to control virus replication and restore CD4+ T-cell count.
Study: NCT02975193

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer task assessing cognition
Description: Participants will complete a short computer game to assess cognition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computer task assessing cognition
Description: Participants will complete a short computer game to assess cognition.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impulsive-Compulsive Disorders in Parkinson's Disease
Description: Standard clinical questionnaire

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impulsive-Compulsive Disorders in Parkinson's Disease
Description: Standard clinical questionnaire

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation Surgery
Description: DBS surgery for the implantation of electrodes for the treatment of motor disorders.
Study: NCT01519765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buccal Misoprostol
Description: Buccal rather than Vaginal misoprostol for induction of labor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal misoprostol
Description: Vaginal rather than buccal misoprostol for induction of labor
Study: NCT04819256

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PACE-It mobile application
Description: Care co-ordination platform
Study: NCT01806857

Intervention type: DRUG
Group type: OTHER
Intervention: Nuedexta
Description: Nuedexta PO (by mouth) for 28 ± 3 days

Intervention type: DRUG
Group type: OTHER
Intervention: Nuedexta
Description: Nuedexta PO (by mouth) for 28 ± 3 days

Intervention type: DRUG
Group type: OTHER
Intervention: Matching Placebo
Description: matching placebo PO (by mouth) for 28 ± 3 days

Intervention type: DRUG
Group type: OTHER
Intervention: Matching Placebo
Description: matching placebo PO (by mouth) for 28 ± 3 days
Study: NCT03752008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Play (AP)
Description: This intervention focused on promoting PA in preschoolers through structured, teacher-led activities that could be incorporated into daily curriculum. Teachers attended a 3-hour workshop that included presentation and discussion of 1) the importance of daily physical activity for children's health and development, 2) teachers' beliefs and barriers to promoting PA, and 3) the Active Play! Intervention materials. Teachers were introduced to and given the Active Play! Fun Physical Activities for Young Children Book and Digital Video Disk (DVD), which promotes PA and fundamental movement skills in young children. Clips of the DVD demonstrating various activities were shown and activities were modeled. Examples of activities include jumping on bubble wrap, hula hoop limbo and an indoor obstacle course. The end of the book has a suggested curriculum that teachers could follow. Centers in the Active Play! intervention also received a set of portable toys needed for the suggested activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor Play (OP)
Description: This intervention focused on promoting outdoor time in preschoolers as a means to increasing their PA, using both child initiated and teacher-led activities. The training and materials were designed to emphasize the teacher's own connection with nature, the benefits of outdoor time for children and adults, and problem solving around barriers encountered. Teachers at participating centers attended one 3-hour workshop (delivered at the childcare center) that focused on having participants recognize their own connection with the natural world and how to transmit that to the next generation. Teachers were given hats and gloves for themselves, a set of rain jackets and boots for the preschoolers, and ideas on what children could do outdoors to be active.
Study: NCT04754750

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA]
Study: NCT01721057

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cDMARD
Description: Conventional disease-modifying anti-rheumatic drug as a background therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cDMARD
Description: Conventional disease-modifying anti-rheumatic drug as a background therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cDMARD
Description: Conventional disease-modifying anti-rheumatic drug as a background therapy
Study: NCT00710736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARRY-334543, EGFR/ErbB2 inhibitor; oral
Description: multiple dose, escalating

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, 5-fluorouracil prodrug; oral
Description: multiple dose, single schedule
Study: NCT03700580

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrogel treatment
Description: Hydrogel dressing containing water, carboxymethyl cellulose and sodium alginate in non-specified proportions, purchased in bulk amounts was sterile dispensed in smaller amounts (200 g) for frequent use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1G10
Description: P1G10 containing dressing composed by 8% Polawax, 6% liquid vaseline, 0.06% butylated hydroxytoluene, 0.15% Nipagin, 5% propyleneglycol, 0.1% Nipazol, 0.1% ethylenediaminetetraacetate disodium salt, 0.03% methyl-aminopropanol-95, 0.3% Imidazolidinyl urea, 2% Cyclomethicone, 78.2% distilled water. A single batch of the formulation was made and used throughout the intervention. A sample of this preparation was used to assess the extended stability of the formulation. The formulation was dispensed into 100 g dispensers for weekly use.
Study: NCT01677156

Intervention type: DIAGNOSTIC_TEST
Intervention: CORUS CAD (ASGES)
Description: Age/Sex/Gene Expression Score - ASGES
Study: NCT03517787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES+TE
Description: Group receive FES+therapeutic exercise during 6 weeks (twice a week). Altogether 8 exercises are conducted, each done 3 sets and 12 repetitions during first three weeks and 4 sets during last three weeks of intervention).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TE
Description: Group perform only therapeutic exercise. Exercises are the same between all 4 groups.

Intervention type: OTHER
Group type: OTHER
Intervention: REF-FES+TE
Description: Group perform FES+TE, but only participate in 1 session to collect reference data.

Intervention type: OTHER
Group type: OTHER
Intervention: REF-TE
Description: Group perform only therapeutic exercise, but only participate in 1 session to collect reference data.
Study: NCT00121784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1
Study: NCT02663050

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio taping
Description: Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio taping
Description: Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID's
Description: twice a daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID's
Description: twice a daily
Study: NCT02090413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dimethyl fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: enteric-coated capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: enteric-coated capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA-Placebo
Description: matched placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA-Placebo
Description: matched placebo
Study: NCT00789880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: Administration of oral vitamin D3 at 4000IU

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of oral Vitamin D3 placebo
Study: NCT00445705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Part A: Placebo every 12 hours for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: AGN 203818 3 mg every 12 hours for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: AGN 203818 20 mg every 12 hours for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN 203818
Description: Part A: AGN 203818 60 mg every 12 hours for 4 weeks
Study: NCT05269342

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nurse-led counseling and after intervention
Description: the nurse-led counseling and after intervention exercise (NUCAI), in patients with HNC
Study: NCT02717884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranylcypromine
Description: TCP p.o., daily either 20, 40\*\*, 60\*\*, 80\*\* mg/day, (28d/cycle)~\*\*TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: all-trans retinoic acid
Description: 45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: 40mg s.c. (days 1-10)
Study: NCT00217243

Intervention type: OTHER
Intervention: Evoked fields before and after a local block (Xylocaine)
Description: MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
Study: NCT02281357

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Tralokinumab dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dose
Study: NCT02046096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Günther Tulip® Vena Cava Filter
Description: Temporary or permanent filter placement for the prevention of pulmonary embolism

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cook Celect® Vena Cava Filters
Description: Temporary or permanent filter placement for the prevention of pulmonary embolism
Study: NCT02218242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intraoperative ultrasound
Description: Intraoperative ultrasound will be performed at the completion of the standard lung cancer resection with mediastinal lymph node dissection. This evaluation will be performed by a different surgeon from the primary surgeon performing the operation to minimize operator variability with the ultrasound system and help control for bias. Additional lymph nodes identified will be resected and sent for pathologic evaluation. It is anticipated that this additional evaluation and treatment should take no more than 30 minutes and as such a time limit of 30 minutes from introduction of the ultrasound probe into the surgical field will be set.
Study: NCT02741869

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photodynamic therapy (Ondine: MRSAid™)
Description: Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
Study: NCT01640912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RXI-109
Description: Single intradermal injection of RXI-109 at incision sites

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intradermal injection of placebo at incision sites
Study: NCT01753128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imipramine
Study: NCT01878942

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Capsules containing mannitol looking identical to LSD~per os

Intervention type: DRUG
Group type: OTHER
Intervention: LSD
Description: 200µg per os, single dose
Study: NCT03506737

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional exercise protocol
Description: Breathing exercises and global active exercises of the upper and lower limbs while in the upright seated position

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle ergometer exercise protocol
Description: Stationary cycle ergometer exercise while in the upright seated position for 20 minutes. The protocol will be performed intermittently with 5 periods; each period consists of 3 minutes of cycling followed by 1-minute of rest.
Study: NCT03043521

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexlansoprazole 60 MG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 100mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-12420 200mg
Study: NCT02743884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Warming
Description: 30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal Cooling
Description: 30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
Study: NCT02478970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Konan SP4000
Description: current standard of care at Kellogg Eye Center

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Konan SP4000
Description: current standard of care at Kellogg Eye Center

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIDEK CEM-350
Description: newly marketed device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NIDEK CEM-350
Description: newly marketed device